ARCH THERAPEUTICS Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AT</div>
ARTH -- USA Stock  

USD 0.19  0.01  5.56%

ARCH THERAPEUTICS Invested Capital Average is most likely to increase significantly in the upcoming years. The last year's value of Invested Capital Average was reported at 149,109. The current Market Capitalization is estimated to increase to about 57 M, while Average Assets are projected to decrease to roughly 3.6 M. Despite nearly stable basic indicators, ARCH THERAPEUTICS is not utilizing all of its potentials. The latest stock price disturbance, may contribute to a mid-run swings for the stockholders. The company follows the market closely. We can now examine ARCH THERAPEUTICS as a potential investment option for your portfolios.
Published over a month ago
View all stories for ARCH THERAPEUTICS | View All Stories
When the last time you checked ARCH THERAPEUTICS (OTC:ARTH) fundamentals?
We provide trade recommendation to complement the latest expert consensus on ARCH THERAPEUTICS INC. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available right now. ARCH THERAPEUTICS dividends can provide a clue to the current value of the stock. The firm is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include ARCH THERAPEUTICS income statement, its balance sheet, and the statement of cash flows. Potential ARCH THERAPEUTICS investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although ARCH THERAPEUTICS investors may use each financial statement separately, they are all related. The changes in ARCH THERAPEUTICS's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ARCH THERAPEUTICS's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of ARCH THERAPEUTICS fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of ARCH THERAPEUTICS performance into the future periods or doing a reasonable stock valuation. The intrinsic value of ARCH THERAPEUTICS shares is the value that is considered the true value of the share. If the intrinsic value ARCH THERAPEUTICS is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares ARCH THERAPEUTICS. Please read more on our fundamental analysis page.

Watch out for price decline

Please consider monitoring ARCH THERAPEUTICS on a daily basis if you are holding a position in it. ARCH THERAPEUTICS is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as ARCH THERAPEUTICS stock to be traded above the $1 level to remain listed. If ARCH THERAPEUTICS stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

What is ARCH THERAPEUTICS Asset Breakdown?

ARCH THERAPEUTICS INC reports assets on its Balance Sheet. It represents the amount of ARCH THERAPEUTICS resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect ARCH THERAPEUTICS volatility, please check the breakdown of all its fundamentals

How ARCH THERAPEUTICS utilizes its cash?

To perform a cash flow analysis of ARCH THERAPEUTICS, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash ARCH THERAPEUTICS is receiving and how much cash it distributes out in a given period. The ARCH THERAPEUTICS cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. ARCH THERAPEUTICS Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (4.54 Million)

Purchase by James Sulat of 340910 shares of ARCH THERAPEUTICS

Legal trades by ARCH THERAPEUTICS insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
ARCH THERAPEUTICS insider trading alert for perchase of series j warrant (right to buy) by James Sulat, the corporate stakeholder, on 23rd of June 2020. This event was filed by Arch Therapeutics Inc with SEC on 2020-06-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down ARCH THERAPEUTICS Indicators

The current indifference towards the small price fluctuations of ARCH THERAPEUTICS INC could raise concerns from stockholders as the firm it trading at a share price of 0.17 on very low momentum in volume. The company directors and management did not add any value to ARCH THERAPEUTICS INC investors in October. However, most investors can still diversify their portfolios with ARCH THERAPEUTICS INC to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 3.24. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from ARCH THERAPEUTICS INC partners.

Asset Utilization

One of the ways to look at asset utilization of ARCH THERAPEUTICS is to check how much profit was generated for every dollar of assets it reports. ARCH THERAPEUTICS INC owns a negative utilization of current and long term assets of -99.54 %, losing $1.0 for each dollar of current and long term assets held by the firm. Inadequate asset utilization signifies that the company is being less productive with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of ARCH THERAPEUTICS INC shows how discouraging it operates for each dollar spent on its current and long term assets.

Current Assets
3.4 M
Current Assets3.38 Million99.59
Assets Non Current13,978.70.41

ARCH THERAPEUTICS possible throwback in December

Current mean deviation is at 1.49. ARCH THERAPEUTICS INC shows above-average downside volatility for the selected time horizon. We advise investors to inspect ARCH THERAPEUTICS INC further and ensure that all market timing and asset allocation strategies are consistent with the estimation of ARCH THERAPEUTICS future alpha. ARCH THERAPEUTICS INC is a potential penny stock. Although ARCH THERAPEUTICS may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in ARCH THERAPEUTICS INC. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Final Take On ARCH THERAPEUTICS

While some firms within the biotechnology industry are still a little expensive, even after the recent corrections, ARCH THERAPEUTICS may offer a potential longer-term growth to stockholders. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor exit any shares of ARCH THERAPEUTICS at this time. The ARCH THERAPEUTICS INC risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to ARCH THERAPEUTICS.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of ARCH THERAPEUTICS INC. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com